Tranexamic acid is associated with increased mortality in patients with physiological fibrinolysis

Journal of Surgical Research

Volumn 220, Issue , 2017, Pages 438-443

  Moore, Hunter B ^a   Moore, Ernest E ^a,b   Huebner, Benjamin R ^a   Stettler, Gregory R ^a   Nunns, Geoffrey R ^a   Einersen, Peter M ^a   Silliman, Christopher C ^a,c   Sauaia, Angela ^a,d  

^a UNIVERSITY OF COLORADO   (United States)

^b DENVER HEALTH MEDICAL CENTER   (United States)

^c Bonfils Blood Center   (United States)

^d Food Science and Human Nutrition   (United States)

Author keywords

Fibrinolysis; Fibrinolysis shutdown; Tranexamic acid; Trauma; Trauma induced coagulopathy

Indexed keywords

FRESH FROZEN PLASMA; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

ADULT; ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; CRYOPRECIPITATE; ERYTHROCYTE TRANSFUSION; FEMALE; FIBRINOLYTIC THERAPY; HOSPITAL MORTALITY; HUMAN; INJURY SCALE; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; PENETRATING TRAUMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTE TRANSFUSION; THROMBOELASTOGRAPHY; BLOOD TRANSFUSION; COLORADO; EPIDEMIOLOGY; FIBRINOLYSIS; INJURY; MIDDLE AGED; MORTALITY; UTILIZATION; YOUNG ADULT;

ADULT; ANTIFIBRINOLYTIC AGENTS; BLOOD TRANSFUSION; COLORADO; FEMALE; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED; TRANEXAMIC ACID; WOUNDS AND INJURIES; YOUNG ADULT;

EID: 85025817552     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2017.04.028     Document Type: Article

References (34)

1. Moore, H.B., Moore, E.E., Gonzalez, E., et al. Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy. J Trauma Acute Care Surg 77 (2014), 811–817 discussion 817.
2. Moore, H.B., Moore, E.E., Liras, I.N., et al. Acute fibrinolysis shutdown after injury occurs frequently and increases mortality: a multicenter evaluation of 2,540 severely injured patients. J Am Coll Surg 222 (2016), 347–355.
3. Chapman, M.P., Moore, E.E., Ramos, C.R., et al. Fibrinolysis greater than 3% is the critical value for initiation of antifibrinolytic therapy. J Trauma Acute Care Surg 75 (2013), 961–967 discussion 967.
4. Cotton, B.A., Harvin, J.A., Kostousouv, V., et al. Hyperfibrinolysis at admission is an uncommon but highly lethal event associated with shock and prehospital fluid administration. J Trauma Acute Care Surg 73 (2012), 365–370 discussion 370.
5. Schochl, H., Frietsch, T., Pavelka, M., Jambor, C., Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J Trauma 67 (2009), 125–131.
6. Collaborators C-t, Shakur, H., Roberts, I., et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 376 (2010), 23–32.
7. Cole, E., Davenport, R., Willett, K., Brohi, K., Tranexamic acid use in severely injured civilian patients and the effects on outcomes: a prospective cohort study. Ann Surg 261 (2015), 390–394.
8. Myles, P.S., Smith, J.A., Forbes, A., et al. Tranexamic acid in patients undergoing coronary artery surgery. N Engl J Med 376 (2017), 136–148.
9. Barrachina, B., Lopez-Picado, A., Remon, M., et al. Tranexamic acid compared with placebo for reducing total blood loss in hip replacement surgery: a randomized clinical trial. Anesth Analg 122 (2016), 986–995.
10. Meizoso, J.P., Karcutskie, C.A., Ray, J.J., Namias, N., Schulman, C.I., Proctor, K.G., Persistent fibrinolysis shutdown associated with increased mortality in severely injured trauma patients. J Am Coll Surg 224 (2017), 575–582.
11. Hardaway, R.M., Drake, D.C., Prevention of “irreversible” hemorrhagic shock with fibrinolysin. Ann Surg 157 (1963), 39–47.
12. Valle, E.J., Allen, C.J., Van Haren, R.M., et al. Do all trauma patients benefit from tranexamic acid?. J Trauma Acute Care Surg 76 (2014), 1373–1378.
13. Harvin, J.A., Peirce, C.A., Mims, M.M., et al. The impact of tranexamic acid on mortality in injured patients with hyperfibrinolysis. J Trauma Acute Care Surg 78 (2015), 905–911.
14. Moore, E.E., Moore, H.B., Gonzalez, E., et al. Rationale for the selective administration of tranexamic acid to inhibit fibrinolysis in the severely injured patient. Transfusion 56 (2016), S110–S114.
15. Hardaway, R.M., Brune, W.H., Geever, E.F., Burns, J.W., Mock, H.P., Studies on the role of intravascular coagulation in irreversible hemorrhagic shock. Ann Surg 155 (1962), 241–250.
16. Hardaway, R.M., Burns, J.W., Mechanism of action of fibrinolysin in the prevention of irreversible hemorrhagic shock. Ann Surg 157 (1963), 305–309.
17. Reust, D.L., Reeves, S.T., Abernathy, J.H. 3rd, et al. Temporally and regionally disparate differences in plasmin activity by tranexamic acid. Anesth Analg 110 (2010), 694–701.
18. Chen, Y., Chen, Z., Cui, S., Li, Z., Yuan, Z., Topical versus systemic tranexamic acid after total knee and hip arthroplasty: a meta-analysis of randomized controlled trials. Medicine (Baltimore), 95, 2016, e4656.
19. Moore, H.B., Moore, E.E., Gonzalez, E., et al. Plasma is the physiologic buffer of tissue plasminogen activator-mediated fibrinolysis: rationale for plasma-first resuscitation after life-threatening hemorrhage. J Am Coll Surg 220 (2015), 872–879.
20. Moore, H.B., Moore, E.E., Morton, A.P., et al. Shock induced systemic hyperfibrinolysis is attenuated by plasma first resuscitation. J Trauma Acute Care Surg 79 (2015), 897–903.
21. D'Alessandro, A., Moore, H.B., Moore, E.E., et al. Plasma first resuscitation reduces lactate acidosis, enhances redox homeostasis, amino acid and purine catabolism in a rat model of profound hemorrhagic shock. Shock 46 (2016), 173–182.
22. Kozar, R.A., Peng, Z., Zhang, R., et al. Plasma restoration of endothelial glycocalyx in a rodent model of hemorrhagic shock. Anesth Analg 112 (2011), 1289–1295.
23. Peng, Z., Pati, S., Potter, D., et al. Fresh frozen plasma lessens pulmonary endothelial inflammation and hyperpermeability after hemorrhagic shock and is associated with loss of syndecan 1. Shock 40 (2013), 195–202.
24. Ban, K., Peng, Z., Pati, S., Witkov, R.B., Park, P.W., Kozar, R.A., Plasma-mediated gut protection after hemorrhagic shock is lessened in syndecan-1-/- mice. Shock 44 (2015), 452–457.
25. Morrison, J.J., Dubose, J.J., Rasmussen, T.E., Midwinter, M.J., Military application of tranexamic acid in trauma emergency resuscitation (MATTERs) study. Arch Surg 147 (2012), 113–119.
26. Wafaisade, A., Lefering, R., Bouillon, B., et al. Prehospital administration of tranexamic acid in trauma patients. Crit Care, 20, 2016, 143.
27. Rossaint, R., Bouillon, B., Cerny, V., et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care, 20, 2016, 100.
28. Moore, H.B., Moore, E.E., Gonzalez, E., et al. Reperfusion shutdown: delayed onset of fibrinolysis resistance after resuscitation from hemorrhagic shock is associated with increased circulating levels of plasminogen activator inhibitor-1 and postinjury complications. Blood, 128, 2016, 206.
29. Morton, A.P., Moore, E.E., Wohlauer, M.V., et al. Revisiting early postinjury mortality: are they bleeding because they are dying or dying because they are bleeding?. J Surg Res 179 (2013), 5–9.
30. Kutcher, M.E., Ferguson, A.R., Cohen, M.J., A principal component analysis of coagulation after trauma. J Trauma Acute Care Surg 74 (2013), 1223–1229 discussion 1229-1230.
31. Chin, T.L., Moore, E.E., Moore, H.B., et al. A principal component analysis of postinjury viscoelastic assays: clotting factor depletion versus fibrinolysis. Surgery 156 (2014), 570–577.
32. Gonzalez, E., Moore, E.E., Moore, H.B., et al. Goal-directed hemostatic resuscitation of trauma-induced coagulopathy: a pragmatic randomized clinical trial comparing a viscoelastic assay to conventional coagulation assays. Ann Surg 263 (2016), 1051–1059.
33. Holcomb, J.B., Tilley, B.C., Baraniuk, S., et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 313 (2015), 471–482.
34. Henry, D.A., Carless, P.A., Moxey, A.J., et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane database Syst Rev, 2011, CD001886.